Abstract
We aimed to analyze the epidemiology, clinical characteristics, and outcome of patients with Hodgkin lymphoma (HL) diagnosed in Tyrol. All patients with newly diagnosed HL between 1993 and 2005 were included in this study. Among the 158 cases included, nodular lymphocytic predominant HL (nodular paragranuloma) was identified in ten cases (6%) whereas the majority of patients had classical Hodgkin lymphoma. Age (p < 0.01), sex (p = 0.03), risk groups according to the German Hodgkin Study Group stratification (p < 0.01), and bone marrow infiltration (p < 0.01) were of prognostic significance considering overall survival (OS) whereas histological subtype and bulky disease were not. The 5- and 10-year OS rates for the total group were 89% and 85%, respectively. Notably, in patients with advanced-stage HL (n = 49), combined modality treatment resulted in significantly better OS than chemotherapy alone (p = 0.01). Three patients developed a second hematological malignancy and one patient developed breast cancer. However, five patients (3%) had a malignant hematological disorder before occurrence of HL. Concerning treatment-related toxicity, bleomycin-associated lung toxicity was observed in six (4%) patients and five (3%) developed lethal treatment-related infectious complications. Our results provide evidence that the incidence rate of HL in Tyrol is comparable to other Western countries. Modern risk-adapted treatment results in excellent long-term prognosis but may be complicated by serious nonhematological side effects, in particular, infections and bleomycin-induced lung toxicity. Furthermore, 3% of HL patients had an antecedent malignant hematological disease before occurrence of HL.
Similar content being viewed by others
References
Parkin DM, Muir CS (1992) Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 45–173
Cartwright RA, Gilman EA, Gurney KA (1999) Time trends in incidence of haematological malignancies and related conditions. Br J Haematol 106:281–295. doi:10.1046/j.1365-2141.1999.01480.x
Tzankov A, Dirnhofer S (2006) Pathobiology of classical Hodgkin lymphoma. Pathobiology 73:107–125. doi:10.1159/000095558
Kuppers R, Rajewsky K (1998) The origin of Hodgkin and Reed/Sternberg cells in Hodgkin’s disease. Annu Rev Immunol 16:471–493. doi:10.1146/annurev.immunol.16.1.471
Jaffe ES, Lee Harris N, Stein H, Vardiman JW (2001) World Health Organization Classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues. IARC Press, Lyon
Correa P, O’Conor GT (1971) Epidemiologic patterns of Hodgkin’s disease. Int J Cancer 8:192–201. doi:10.1002/ijc.2910080203
Gutensohn N, Cole P (1981) Childhood social environment and Hodgkin’s disease. N Engl J Med 304:135–140
Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P et al (1997) Epstein-Barr virus-associated Hodgkin’s disease: epidemiologic characteristics in international data. Int J Cancer 70:375–382. doi:10.1002/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T
Jarrett RF, MacKenzie J (1999) Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin’s disease. Semin Hematol 36:260–269
Alexander FE, Ricketts TJ, McKinney PA, Cartwright RA (1991) Community lifestyle characteristics and incidence of Hodgkin’s disease in young people. Int J Cancer 48:10–14
Keegan TH, Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA et al (2005) Epstein-Barr virus as a marker of survival after Hodgkin’s lymphoma: a population-based study. J Clin Oncol 23:7604–7613. doi:10.1200/JCO.2005.02.6310
Jarrett RF, Stark GL, White J, Angus B, Alexander FE, Krajewski AS et al (2005) Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 106:2444–2451. doi:10.1182/blood-2004-09-3759
Krugmann J, Tzankov A, Gschwendtner A, Fischhofer M, Greil R, Fend F et al (2003) Longer failure-free survival interval of Epstein-Barr virus-associated classical Hodgkin’s lymphoma: a single-institution study. Mod Pathol 16:566–573. doi:10.1097/01.MP.0000071843.09960.BF
Weiss LM, Strickler JG, Warnke RA, Purtilo DT, Sklar J (1987) Epstein-Barr viral DNA in tissues of Hodgkin’s disease. Am J Pathol 129:86–91
Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS (1991) Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease. Lancet 337:320–322. doi:10.1016/0140-6736(91)90943-J
Horwitz SM, Horning SJ (2000) Advances in the treatment of Hodgkin’s lymphoma. Curr Opin Hematol 7:235–240. doi:10.1097/00062752-200007000-00006
Rosenberg SA (1996) The management of Hodgkin’s disease: half a century of change. The Kaplan Memorial Lecture. Ann Oncol 7:555–560
Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22:2835–2841. doi:10.1200/JCO.2004.12.170
Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M et al (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3601–3608. doi:10.1200/JCO.2003.03.023
Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA et al (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin’s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634–4642. doi:10.1200/JCO.2005.09.085
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478–1484
Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C et al (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198–9207. doi:10.1200/JCO.2005.02.907
Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395. doi:10.1056/NEJMoa022473
Hoppe RT (1997) Hodgkin’s disease: complications of therapy and excess mortality. Ann Oncol 8(Suppl 1):115–118. doi:10.1023/A:1008238908676
Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van’t Veer MB, Bartelink H, van Leeuwen FE (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439. doi:10.1200/JCO.2003.07.131
Diehl V, Fuchs M (2007) Early, intermediate and advanced Hodgkin’s lymphoma: modern treatment strategies. Ann Oncol 18(Suppl 9):71–79. doi:10.1093/annonc/mdm297
Tzankov A, Zimpfer A, Pehrs AC, Lugli A, Went P, Maurer R et al (2003) Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 16:1141–1147. doi:10.1097/01.MP.0000093627.51090.3F
Segi M, Fujisaku S, Kurihara M, Narai Y, Sasajima K (1960) The age-adjusted death rates for malignant neoplasms in some selected sites in 23 countries in 1954–1955 and their geographical correlation. Tohoku J Exp Med 72:91–103
Ries LA, Kosary CL, Hankey BF, Miller BA, Clegg LX, Edwards BK (2000) SEER cancer statistics review, 1973–1996. NIH Pub. No.99-2789. National Cancer Institute, Bethesda
Micheli A, Mugno E, Krogh V, Quinn MJ, Coleman M, Hakulinen T et al (2002) Cancer prevalence in European registry areas. Ann Oncol 13:840–865. doi:10.1093/annonc/mdf127
Rodriguez-Abreu D, Bordoni A, Zucca E (2007) Epidemiology of hematological malignancies. Ann Oncol 18(Suppl 1):3–8. doi:10.1093/annonc/mdl443
Josting A, Wiedenmann S, Franklin J, May M, Sieber M, Wolf J et al (2003) Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin’s disease: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:3440–3446. doi:10.1200/JCO.2003.07.160
Behringer K, Josting A, Schiller P, Eich HT, Bredenfeld H, Diehl V et al (2004) Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 15:1079–1085. doi:10.1093/annonc/mdh273
Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H et al (2007) Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol 25:1489–1497. doi:10.1200/JCO.2006.09.0936
Munker R, Grutzner S, Hiller E, Aydemir U, Enne W, Dietzfelbinger H et al (1999) Second malignancies after Hodgkin’s disease: the Munich experience. Ann Hematol 78:544–554. doi:10.1007/s002770050556
Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC et al (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100:1989–1996. doi:10.1182/blood-2002-02-0634
van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH et al (1994) Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 12:312–325
Fong D, Kaiser A, Spizzo G, Gastl G, Tzankov A (2005) Hodgkin’s disease variant of Richter’s syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine. Br J Haematol 129:199–205. doi:10.1111/j.1365-2141.2005.05426.x
Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V (2000) Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group (GHSG). Ann Oncol 11:1105–1114. doi:10.1023/A:1008301225839
Dorr RT (1992) Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. Semin Oncol 19:3–8
Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF (2006) Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer 64:806–811. doi:10.1002/1097-0142(19890815)64:4<806::AID-CNCR2820640407>3.0.CO;2-X
Holoye PY, Luna MA, MacKay B, Bedrossian CW (1978) Bleomycin hypersensitivity pneumonitis. Ann Intern Med 88:47–49
Van Barneveld PW, van der Mark TW, Sleijfer DT, Mulder NH, Koops HS, Sluiter HJ et al (1984) Predictive factors for bleomycin-induced pneumonitis. Am Rev Respir Dis 130:1078–1081
Dearnaley DP, Horwich A, A’Hern R, Nicholls J, Jay G, Hendry WF et al (1991) Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up. Eur J Cancer 27:684–691
Jules-Elysee K, White DA (1990) Bleomycin-induced pulmonary toxicity. Clin Chest Med 11:1–20
Levi JA, Raghavan D, Harvey V, Thompson D, Sandeman T, Gill G et al (1993) The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 11:1300–1305
Real E, Roca MJ, Vinuales A, Pastor E, Grau E (1999) Life threatening lung toxicity induced by low doses of bleomycin in a patient with Hodgkin’s disease. Haematologica 84:667–668
Bredenfeld H, Franklin J, Nogova L, Josting A, Fries S, Mailander V et al (2004) Severe pulmonary toxicity in patients with advanced-stage Hodgkin’s disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 22:2424–2429. doi:10.1200/JCO.2004.09.114
Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 23:7614–7620. doi:10.1200/JCO.2005.02.7243
Dirix LY, Schrijvers D, Druwe P, Van den Brande J, Verhoeven D, van Oosterom AT (1994) Pulmonary toxicity and bleomycin. Lancet 344:56. doi:10.1016/S0140-6736(94)91076-6
Matthews JH (1993) Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. Lancet 342:988. doi:10.1016/0140-6736(93)92033-P
Disclosure or conflict of interest
There is no duality of interest to be disclosed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fong, D., Steurer, M., Greil, R. et al. Hodgkin lymphoma in Tyrol—a population-based study. Ann Hematol 88, 449–456 (2009). https://doi.org/10.1007/s00277-008-0618-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0618-1